Fri, February 4, 2022
Thu, February 3, 2022
Wed, February 2, 2022
Tue, February 1, 2022
Mon, January 31, 2022
Sun, January 30, 2022
Fri, January 28, 2022
Thu, January 27, 2022

Matthew Harrison Maintained (SRPT) at Hold with Decreased Target to $71 on, Feb 1st, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-71-on-feb-1st-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Decreased Target from $92 to $71 on, Feb 1st, 2022.

Matthew has made no other calls on SRPT in the last 4 months.



There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Judah Frommer of "Credit Suisse" Maintained at Hold with Decreased Target to $95 on, Friday, October 15th, 2021


These are the ratings of the 6 analyists that currently disagree with Matthew


  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $105 on, Wednesday, January 26th, 2022
  • Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $150 on, Wednesday, January 5th, 2022
  • Hartaj Singh of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $125 on, Thursday, December 9th, 2021
  • Anupam Rama of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $130 on, Friday, November 5th, 2021
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $145 on, Thursday, November 4th, 2021
  • Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $125 on, Tuesday, October 12th, 2021

Publication Contributing Sources